Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BEYOND MEAT, INC.BYND · Entity 6266 | Chief Accounting Officer | May 10, 2026 | June 02, 2026 |
| Calidi Biotherapeutics, Inc.CLDI · Entity 8408 | Chief Acctg Officer, Int. CFO | September 12, 2023 | September 25, 2023 |
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Sr.VP/Chief Accounting Officer | August 03, 2020 | August 05, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BEYOND MEAT, INC.
Report date May 10, 2026 · Filed June 02, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2036-05-09 | Direct | 236,221 |
Reported balance
After 2026-05-10 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-10 · Grant · Acquired 236,221 · Balance 236,221 F1: Stock option granted under the 2026 Employment Inducement Equity Incentive Plan on May 10, 2026; 1/4th of the total number of shares subject to the option award vests and becomes exercisable on January 12, 2027, and 1/48th of the total number of shares subject to the option award vests and becomes exercisable monthly thereafter, such that the option becomes fully vested and exercisable on January 12, 2030, subject to the acceleration provisions of an Executive Change in Control Severance Agreement by and between the Reporting Person and the Issuer, and continued service by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option granted under the 2026 Employment Inducement Equity Incentive Plan on May 10, 2026; 1/4th of the total number of shares subject to the option award vests and becomes exercisable on January 12, 2027, and 1/48th of the total number of shares subject to the option award vests and becomes exercisable monthly thereafter, such that the option becomes fully vested and exercisable on January 12, 2030, subject to the acceleration provisions of an Executive Change in Control Severance Agreement by and between the Reporting Person and the Issuer, and continued service by the Reporting Person.
Calidi Biotherapeutics, Inc.
Report date September 12, 2023 · Filed September 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 278,790 |
Reported balance
Holding disclosure · report date 2023-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 278,790 F1: Reflects shares of common stock, par value $0.0001 per share (the "Common Stock"),of Calidi Biotherapeutics, Inc.(f/k/a First Light Acquisition Group, Inc.), a Delaware corporation ("New Calidi" or the "Issuer"). Pursuant to the Agreement and Plan of Merger, dated January 9, 2023, as amended on February 9, 2023 and June 16, 2023 (the "Merger Agreement"), by and among First Light Acquisition Group, Inc. ("FLAG"), FLAG Merger Sub, Inc. ("Merger Sub"), First Light Acquisition Group, LLC, Allan Camaisa and Calidi Biotherapeutics, Inc., a Nevada corporation ("Old Calidi"), on September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger as a wholly-owned subsidiary of the Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). Upon the consummation of the Business Combination, (the "Closing"), (cont'd. in FN 2) F2: (cont'd from FN 1) each share of common stock of Old Calidi (the "Old Calidi Common Stock") outstanding as of the time of the merger (the "Effective Time") converted into the right to receive approximately 0.41 share (the "Conversion Ratio") of the Issuer's Common Stock. |
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2031-12-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: The Reporting Person was originally granted stock options by Old Calidi (the "Calidi Options"), which was assumed by the Issuer at the Effective Time and automatically converted into options exercisable for the Issuer's Common Stock (the "Assumed Options"), subject to the terms and conditions set forth in the Old Calidi 2016 Equity Incentive Plan, as amended from time to time, and the Old Calidi 2019 Equity Incentive Plan, as amended from time to time (together, the "Calidi Equity Incentive Plan"). Each Assumed Option has the right to acquire a number of shares of Issuer's Common Stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Old Calidi Common Stock subject to such Calidi Option immediately prior to the Effective Time, (cont'd in FN 4) F4: (cont'd from FN 3) multiplied by (B) the Conversion Ratio; (1) at an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of such Calidi Option immediately prior to the Effective Time, divided by (B) the Conversion Ratio; and (2) subject to the same vesting schedule as such Calidi Option. The exercise price and the number of shares of Issuer's Common Stock underlying the Assumed Options reflects the Conversion Ratio adjustment made in connection with the Closing. F5: These Incentive Stock Options were granted on December 2, 2021 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.01 · Expires 2032-02-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The Reporting Person was originally granted stock options by Old Calidi (the "Calidi Options"), which was assumed by the Issuer at the Effective Time and automatically converted into options exercisable for the Issuer's Common Stock (the "Assumed Options"), subject to the terms and conditions set forth in the Old Calidi 2016 Equity Incentive Plan, as amended from time to time, and the Old Calidi 2019 Equity Incentive Plan, as amended from time to time (together, the "Calidi Equity Incentive Plan"). Each Assumed Option has the right to acquire a number of shares of Issuer's Common Stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Old Calidi Common Stock subject to such Calidi Option immediately prior to the Effective Time, (cont'd in FN 4) F4: (cont'd from FN 3) multiplied by (B) the Conversion Ratio; (1) at an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of such Calidi Option immediately prior to the Effective Time, divided by (B) the Conversion Ratio; and (2) subject to the same vesting schedule as such Calidi Option. The exercise price and the number of shares of Issuer's Common Stock underlying the Assumed Options reflects the Conversion Ratio adjustment made in connection with the Closing. F6: These Incentive Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.11 · Expires 2032-02-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-09-12 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The Reporting Person was originally granted stock options by Old Calidi (the "Calidi Options"), which was assumed by the Issuer at the Effective Time and automatically converted into options exercisable for the Issuer's Common Stock (the "Assumed Options"), subject to the terms and conditions set forth in the Old Calidi 2016 Equity Incentive Plan, as amended from time to time, and the Old Calidi 2019 Equity Incentive Plan, as amended from time to time (together, the "Calidi Equity Incentive Plan"). Each Assumed Option has the right to acquire a number of shares of Issuer's Common Stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Old Calidi Common Stock subject to such Calidi Option immediately prior to the Effective Time, (cont'd in FN 4) F4: (cont'd from FN 3) multiplied by (B) the Conversion Ratio; (1) at an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of such Calidi Option immediately prior to the Effective Time, divided by (B) the Conversion Ratio; and (2) subject to the same vesting schedule as such Calidi Option. The exercise price and the number of shares of Issuer's Common Stock underlying the Assumed Options reflects the Conversion Ratio adjustment made in connection with the Closing. F7: These Incentive Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of common stock, par value $0.0001 per share (the "Common Stock"),of Calidi Biotherapeutics, Inc.(f/k/a First Light Acquisition Group, Inc.), a Delaware corporation ("New Calidi" or the "Issuer"). Pursuant to the Agreement and Plan of Merger, dated January 9, 2023, as amended on February 9, 2023 and June 16, 2023 (the "Merger Agreement"), by and among First Light Acquisition Group, Inc. ("FLAG"), FLAG Merger Sub, Inc. ("Merger Sub"), First Light Acquisition Group, LLC, Allan Camaisa and Calidi Biotherapeutics, Inc., a Nevada corporation ("Old Calidi"), on September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger as a wholly-owned subsidiary of the Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). Upon the consummation of the Business Combination, (the "Closing"), (cont'd. in FN 2)
F2: (cont'd from FN 1) each share of common stock of Old Calidi (the "Old Calidi Common Stock") outstanding as of the time of the merger (the "Effective Time") converted into the right to receive approximately 0.41 share (the "Conversion Ratio") of the Issuer's Common Stock.
F3: The Reporting Person was originally granted stock options by Old Calidi (the "Calidi Options"), which was assumed by the Issuer at the Effective Time and automatically converted into options exercisable for the Issuer's Common Stock (the "Assumed Options"), subject to the terms and conditions set forth in the Old Calidi 2016 Equity Incentive Plan, as amended from time to time, and the Old Calidi 2019 Equity Incentive Plan, as amended from time to time (together, the "Calidi Equity Incentive Plan"). Each Assumed Option has the right to acquire a number of shares of Issuer's Common Stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Old Calidi Common Stock subject to such Calidi Option immediately prior to the Effective Time, (cont'd in FN 4)
F4: (cont'd from FN 3) multiplied by (B) the Conversion Ratio; (1) at an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of such Calidi Option immediately prior to the Effective Time, divided by (B) the Conversion Ratio; and (2) subject to the same vesting schedule as such Calidi Option. The exercise price and the number of shares of Issuer's Common Stock underlying the Assumed Options reflects the Conversion Ratio adjustment made in connection with the Closing.
F5: These Incentive Stock Options were granted on December 2, 2021 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F6: These Incentive Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F7: These Incentive Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over four years from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Insight Molecular Diagnostics Inc.
Report date August 03, 2020 · Filed August 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2020-08-03 transaction · row 1
1 source rowRow 1 · 2020-08-03 · Purchase · Acquired 5,000 · Balance 15,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2026 Filed May 12, 2026 21:26 UTC | BEYOND MEAT, INC. BYND · Entity 6266 | GrantStock Option (right to buy) · Derivative | 237,718 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001786237-26-000009 · wk-form4_1778621202.xml · derivative · entry 2 Kalajian Tony T · CIK 0001786237 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,718 Underlying: Common Stock · 237,718 shares Expires 2036-05-09 F2 · derivative.exercise_date: Stock option granted under the Plan on May 10, 2026; 1/4th of the total number of shares subject to the option award vests and becomes exercisable on January 12, 2027, and 1/48th of the total number of shares subject to the option award vests and becomes exercisable monthly thereafter, such that the option becomes fully vested and exercisable on January 12, 2030, subject to the acceleration provisions of an Executive Change in Control Severance Agreement by and between the Reporting Person and the Issuer, and continued service by the Reporting Person. Read SEC document |
| May 10, 2026 Filed May 12, 2026 21:26 UTC | BEYOND MEAT, INC. BYND · Entity 6266 | GrantCommon Stock | 180,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001786237-26-000009 · wk-form4_1778621202.xml · nonDerivative · entry 1 Kalajian Tony T · CIK 0001786237 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,051 F1 · shares: RSUs granted under the 2026 Employment Inducement Equity Incentive Plan ("Plan") on May 10, 2026; 1/4th of the total number of shares subject to the RSU award vests on January 12, 2027, and 1/16th of the total number of shares subject to the RSU award vests each quarter thereafter, until the award is fully vested on January 12, 2030, subject to the acceleration provisions of an Executive Change in Control Severance Agreement by and between the Reporting Person and the Issuer, and continued service by the Reporting Person. Read SEC document |
| May 10, 2026 Filed Jun 2, 2026 21:58 UTC Amendment | BEYOND MEAT, INC. BYND · Entity 6266 | GrantStock Option (right to buy) · Derivative | 236,221 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001786237-26-000011 · wk-form4a_1780437492.xml · derivative · entry 1 Kalajian Tony T · CIK 0001786237 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,221 Underlying: Common Stock · 236,221 shares Expires 2036-05-09 F1 · derivative.exercise_date: Stock option granted under the 2026 Employment Inducement Equity Incentive Plan on May 10, 2026; 1/4th of the total number of shares subject to the option award vests and becomes exercisable on January 12, 2027, and 1/48th of the total number of shares subject to the option award vests and becomes exercisable monthly thereafter, such that the option becomes fully vested and exercisable on January 12, 2030, subject to the acceleration provisions of an Executive Change in Control Severance Agreement by and between the Reporting Person and the Issuer, and continued service by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 23:34 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 5,000 | $1.31 | $6,533.00 |
DisclosureSEC source: 0001493152-20-014770 · ownership.xml · nonDerivative · entry 1 KALAJIAN TONY T · CIK 0001786237 · Sr.VP/Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 02:53 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to purchase common stock · Derivative | 204,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-20-002155 · ownership.xml · derivative · entry 1 KALAJIAN TONY T · CIK 0001786237 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on February 10, 2020 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 21:28 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 10,000 | $1.98 | $19,800.00 |
DisclosureSEC source: 0001209191-19-049683 · doc4.xml · nonDerivative · entry 1 KALAJIAN TONY T · CIK 0001786237 · SVP-Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price of $1.98 per share represents a weighted average of prices ranging from $1.94 to $1.987 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.